Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment
Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Despite the availability of effective anti-tuberculosis agents that exist to treat this
illness, hepatotoxicity during first-line drugs anti-tuberculosis medications (ATT) such as
isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) is not uncommon and limit their use.
There is no consensus on method of the reintroduction of anti-TB medications. The risk of
reintroducing of a anti-TB medications could be hazardous. There are several differences
between the guidelines from the ATS, BTS and the Task Force of the European Respiratory
Society, the WHO and the International Union Against Tuberculosis and Lung Disease about the
methods of reintroducing of anti-TB medications.
The investigators plan to do a prospective study to evaluate the outcome and safety of
reintroduction of anti-TB medications after resolution of hepatitis during anti-TB treatment
among TB patients in the investigators hospital.